Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticilimumab in Refractory Metastatic Colorectal Cancer
NCT00313794Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2006
- Primary completion
- Jun 2008
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tremelimumab in colorectal cancer (CRC), sponsored by AstraZeneca. Primary endpoint: Best Overall Response Rate at 18 months. Started May 2006; status: completed.
02
Drugs
tremelimumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00313794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00313794.